Last quarter (Q4 2023), Ovid Therapeutics's total revenue was $141.56K, a decrease of -90.58% from the same quarter last year. In Q4, Ovid Therapeutics's net income was $-15.32M. See Ovid Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 391.69K	$ 391.69K	$ 1.50M	$ 208.38M	$ 12.62M	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 391.69K	$ 391.69K	$ 1.50M	-	-	-
Operating Expense	$ 29.76M	$ 59.67M	$ -57.05M	$ -84.17M	$ 94.05M	$ 61.41M
Operating Income	$ -59.28M	$ -59.28M	$ -55.55M	$ -84.22M	$ -81.43M	$ -61.41M
Net Non Operating Interest Income Expense	-	-	-	-	-	$ 948.22K
Other Income Expense	$ -6.94M	$ -6.94M	$ -1.38M	$ -208.38M	$ 395.40K	$ 948.22K
Pretax Income	$ -52.34M	$ -52.34M	$ -54.17M	$ 124.16M	$ -81.04M	$ -60.46M
Tax Provision	-	-	-	$ 1.33M	$ 0.00	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -52.34M	$ -52.34M	$ -54.17M	$ 122.83M	$ -81.04M	$ -60.46M
Basic EPS	$ -0.75	$ -0.74	$ -0.77	$ 1.78	$ -1.39	$ -1.54
Diluted EPS	$ -0.75	$ -0.74	$ -0.77	$ 1.76	$ -1.39	$ -1.54
Basic Average Shares	$ 282.32M	$ 70.58M	$ 70.42M	$ 67.48M	$ 58.45M	$ 39.22M
Diluted Average Shares	$ 282.32M	$ 70.58M	$ 70.42M	$ 68.07M	$ 58.45M	$ 39.22M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 29.76M	$ 59.67M	$ -57.05M	$ -84.17M	$ 94.05M	$ 61.41M
Net Income From Continuing And Discontinued Operation	$ -52.34M	$ -52.34M	$ -54.17M	$ 122.83M	$ -81.04M	$ -60.46M
Normalized Income	$ -30.80M	$ -41.35M	-	-	$ -81.04M	$ -60.46M
Interest Expense	-	-	-	-	-	-
EBIT	$ -52.34M	$ -52.34M	$ -54.17M	$ 124.16M	$ -81.43M	$ -61.41M
EBITDA	$ -50.74M	$ -50.74M	$ -52.79M	$ 124.40M	$ -81.12M	$ -61.15M

Currency in USD

Ovid Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing